Hypereosinophilic syndrome

2 trials 1 recruiting MedDRA PT
2 Registered trials
1 Recruiting
1 Unique sponsors
1 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Monoclonal antibody 1 substance
Phase III: 2

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase III

2 trials
  • Glaxosmithkline Research & Development Limited Commercial
    IMP not specified
    2023-510110-36-00 2 countries 2022 n=7
    Ended
  • Glaxosmithkline Research & Development Limited Commercial
    DEPEMOKIMAB
    2023-510346-25-00 9 countries 2022 n=36
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Glaxosmithkline Research & Development Limited Commercial 2 Phase III 1
New trials by year
2022
2
← All indication landscapes